NASDAQ
WINT

Windtree Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Windtree Therapeutics Inc Stock Price

Vitals

Today's Low:
$1.0508
Today's High:
$1.09
Open Price:
$1.09
52W Low:
$1.02
52W High:
$21.0015
Prev. Close:
$1.08
Volume:
33523

Company Statistics

Market Cap.:
$5.56 million
Book Value:
2.254
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$-17787000
Profit Margin:
0%
Return on Assets TTM:
-20.63%
Return on Equity TTM:
-158.83%

Company Profile

Windtree Therapeutics Inc had its IPO on 1995-08-08 under the ticker symbol WINT.

The company operates in the Healthcare sector and Biotechnology industry. Windtree Therapeutics Inc has a staff strength of 20 employees.

Stock update

Shares of Windtree Therapeutics Inc opened at $1.09 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.05 - $1.09, and closed at $1.08.

This is a 0% increase from the previous day's closing price.

A total volume of 33,523 shares were traded at the close of the day’s session.

In the last one week, shares of Windtree Therapeutics Inc have slipped by -8.47%.

Windtree Therapeutics Inc's Key Ratios

Windtree Therapeutics Inc has a market cap of $5.56 million, indicating a price to book ratio of 0.3959 and a price to sales ratio of 660.5268.

In the last 12-months Windtree Therapeutics Inc’s revenue was $0 with a gross profit of $-17787000 and an EBITDA of $-15153000. The EBITDA ratio measures Windtree Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Windtree Therapeutics Inc’s operating margin was 0% while its return on assets stood at -20.63% with a return of equity of -158.83%.

In Q2, Windtree Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.

Windtree Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-21.9 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Windtree Therapeutics Inc’s profitability.

Windtree Therapeutics Inc stock is trading at a EV to sales ratio of 706.0804 and a EV to EBITDA ratio of -0.0283. Its price to sales ratio in the trailing 12-months stood at 660.5268.

Windtree Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$40.58 million
Total Liabilities
$3.79 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Windtree Therapeutics Inc ended 2024 with $40.58 million in total assets and $0 in total liabilities. Its intangible assets were valued at $40.58 million while shareholder equity stood at $11.60 million.

Windtree Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $3.79 million in other current liabilities, 5000.00 in common stock, $-835244000.00 in retained earnings and $0.00 in goodwill. Its cash balance stood at $11.47 million and cash and short-term investments were $11.47 million. The company’s total short-term debt was $1,099,000 while long-term debt stood at $0.

Windtree Therapeutics Inc’s total current assets stands at $13.32 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $964000.00 and inventory worth $0.

In 2024, Windtree Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Windtree Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$1.08
52-Week High
$21.0015
52-Week Low
$1.02
Analyst Target Price
$5

Windtree Therapeutics Inc stock is currently trading at $1.08 per share. It touched a 52-week high of $21.0015 and a 52-week low of $21.0015. Analysts tracking the stock have a 12-month average target price of $5.

Its 50-day moving average was $1.29 and 200-day moving average was $4.47 The short ratio stood at 0.4 indicating a short percent outstanding of 0%.

Around 960.6% of the company’s stock are held by insiders while 608.8% are held by institutions.

Frequently Asked Questions About Windtree Therapeutics Inc

The stock symbol (also called stock or share ticker) of Windtree Therapeutics Inc is WINT

The IPO of Windtree Therapeutics Inc took place on 1995-08-08

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$0.52
0.02
+4.3%
$131.05
-3.05
-2.27%
$2.03
0
0%
BT Group plc (BTGOF)
$1.37
-0.03
-2.14%
$20.75
-0.23
-1.1%
COSYN Ltd (COSYN)
$27.2
-1.22
-4.29%
$677.75
-25.1
-3.57%
Nova Ltd (NVMI)
$117.08
-0.96
-0.81%
$12.04
-0.23
-1.87%
$17.36
-0.18
-1.03%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.

Address

2600 Kelly Road, Warrington, PA, United States, 18976-3622